New combinations promote individualized bladder and prostate cancer care
Investigational combinations, such as androgen deprivation therapy (ADT) plus lutetium 177 (177Lu) PSMA-617 (177Lu-PSMA-617) and androgen receptor (AR) signaling inhibitors in prostate cancer and sacituzumab govitecan-hziy (Trodelvy) plus pembrolizumab (Keytruda) in urothelial carcinoma, may open up increasingly specific treatment options, according to Alicia Morgans, MD, MPH. “During [advances in these fields] it requires continuous learning …
New combinations promote individualized bladder and prostate cancer care Read More »